| PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer F Roncolato, K Lindemann, ML Willson, J Martyn, L Mileshkin Cochrane database of systematic reviews, 2019 | 75 | 2019 |
| Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy FT Roncolato, E Gibbs, CK Lee, R Asher, LC Davies, VJ Gebski, ... Annals of Oncology 28 (8), 1849-1855, 2017 | 36 | 2017 |
| Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC)–Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS) FT Roncolato, D Berton-Rigaud, R O'Connell, A Lanceley, J Sehouli, ... Gynecologic Oncology 148 (1), 36-41, 2018 | 34 | 2018 |
| Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic … B Tran, L Horvath, M Rettig, K Fizazi, MP Lolkema, TB Dorff, R Greil, ... Journal of Clinical Oncology 38 (15_suppl), TPS5590-TPS5590, 2020 | 30 | 2020 |
| Reducing uncertainty: predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer—the GCIG symptom benefit study FT Roncolato, F Joly, R O'Connell, A Lanceley, F Hilpert, L Buizen, ... The Oncologist 22 (9), 1117-1124, 2017 | 26* | 2017 |
| The impact of mismatch repair status in colorectal cancer on the decision to treat with adjuvant chemotherapy: an Australian population-based multicenter study EY He, NJ Hawkins, G Mak, F Roncolato, D Goldstein, W Liauw, ... The oncologist 21 (5), 618-625, 2016 | 18 | 2016 |
| Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study YC Lee, MT King, RL O'Connell, A Lanceley, F Joly, F Hilpert, A Davis, ... International Journal of Gynecologic Cancer 32 (6), 2022 | 16 | 2022 |
| The effect of pulmonary function testing on bleomycin dosing in germ cell tumours FT Roncolato, M Chatfield, B Houghton, G Toner, M Stockler, D Thomson, ... Internal Medicine Journal 46 (8), 893-898, 2016 | 13 | 2016 |
| Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC … FT Roncolato, RL O'Connell, F Joly, A Lanceley, F Hilpert, L Buizen, ... Gynecologic Oncology 156 (1), 45-53, 2020 | 9 | 2020 |
| Effect sizes hypothesized and observed in contemporary phase III trials of targeted and immunological therapies for advanced cancer NJ Lawrence, F Roncolato, A Martin, RJ Simes, MR Stockler JNCI cancer spectrum 2 (4), pky037, 2018 | 7 | 2018 |
| Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer R Campbell, DSJ Costa, MR Stockler, YC Lee, JA Ledermann, D Berton, ... Gynecologic Oncology 166 (2), 254-262, 2022 | 5 | 2022 |
| Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom … F Roncolato, R O'Connell, L Buizen, F Joly, A Lanceley, F Hilpert, ... Journal of Clinical Oncology 34 (15_suppl), 5508-5508, 2016 | 4 | 2016 |
| UNISON-nivolumab then ipilimumab+ nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy C Gedye, DW Pook, LEM Krieger, CA Harris, JC Goh, G Kichenadasse, ... J. Clin. Oncol 39 (325), 10.1200, 2021 | 3 | 2021 |
| Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC). F Roncolato, E Gibbs, C Lee, LC Davies, V Gebski, M Friedlander, ... Journal of Clinical Oncology 34 (15_suppl), 5575-5575, 2016 | 3 | 2016 |
| PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer J Martyn, F Roncolato, ML Willson, K Lindemann, L Mileshkin Cochrane Database of Systematic Reviews 4, 2016 | 3 | 2016 |
| Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy. C Lee, E Gibbs, FT Roncolato, LC Davies, C Le Maignan, W Meier, ... Journal of Clinical Oncology 33 (15_suppl), 5547-5547, 2015 | 3 | 2015 |
| Patient-reported outcomes in ovarian cancer: facilitating and enhancing the reporting of symptoms, adverse events, and subjective benefit of treatment in clinical trials and … R Campbell, MT King, MR Stockler, YC Lee, FT Roncolato, ... Patient Related Outcome Measures, 111-126, 2023 | 2 | 2023 |
| Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab+ nivolumab in advanced nonclear cell renal cell … C Conduit, G Kichenadasse, CA Harris, H Gurney, T Ferguson, F Parnis, ... Journal of Clinical Oncology 40 (16_suppl), 4537-4537, 2022 | 2 | 2022 |
| Ipilimumab+ nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab+ nivolumab in … C Gedye, DW Pook, LEM Krieger, C Harris, JC Goh, G Kichenadasse, ... J Clin Oncol 39 (suppl 15), 4565, 2021 | 2 | 2021 |
| DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo … T Niazi, S Williams, ID Davis, MR Stockler, AJ Martin, W Hague, ... Journal of Clinical Oncology 38 (6_suppl), TPS385-TPS385, 2020 | 2 | 2020 |
